SCHEMBL24927441

SCHEMBL24927441

C=CC(=O)N1CCC(OCC)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 4/20 0.43
TEAD3 Q99594 2/20 0.43
KMT2A Q03164 2/20 0.41
TET3 O43151 1/20 0.41
FBXL19 Q6PCT2 1/20 0.41
CXXC5 Q7LFL8 1/20 0.41
TET1 Q8NFU7 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
CXXC4 Q9H2H0 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
GAA P10253 1/20 0.38
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 1/20 0.36
JAK1 P23458 1/20 0.35
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35
BTK Q06187 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24037593 0.84 KMT2A (0.36) TEAD1TEAD3KMT2ATET3FBXL19
SCHEMBL24492438 0.82 BTK (0.40) JAK1BTKJAK3
SCHEMBL24492173 0.82 BTK (0.40) JAK1BTKJAK3
SCHEMBL28851673 0.81 GAA (0.42) GAAMAPTALDH1A1THRBATM
SCHEMBL16281594 0.79 TEAD1 (0.43) TEAD1TEAD3KMT2ATET3FBXL19
SCHEMBL4572154 0.79 MAPT (0.44) GAASMN1; SMN2MAPTTHRBATM
SCHEMBL17672505 0.79 GAA (0.41) KMT2AGAAMAPTALDH1A1JAK1
SCHEMBL23328751 0.79 TEAD1 (0.45) TEAD1TEAD3GAABTKJAK3
SCHEMBL28426382 0.78 TEAD1 (0.41) TEAD1TEAD3KMT2ATET3FBXL19
SCHEMBL6499004 0.78 MAPT (0.62) KMT2AGAANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES ERBB2, EGFR, ERBB3 TEAD1 1331/4885TEAD3 609/4885KMT2A 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.